Premium
Interleukin‐10–592C/A, –819C/T and –1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients
Author(s) -
Ezzidi Intissar,
Mtiraoui Nabil,
Kacem Maha,
Mallat Samir G.,
Mohamed Manel Ben Hadj,
Chaieb Molka,
Mahjoub Touhami,
Almawi Wassim Y.
Publication year - 2009
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2008.03337.x
Subject(s) - haplotype , medicine , genotype , diabetic nephropathy , type 2 diabetes , genotyping , nephropathy , endocrinology , polymorphism (computer science) , allele , type 2 diabetes mellitus , biology , gastroenterology , diabetes mellitus , genetics , gene
Summary Background The Interleukin (IL)‐10 polymorphic variants –1082G/A, –819C/T and –592C/A were linked with obesity, metabolic syndrome, and type 2 diabetes (T2DM). We investigated the hypothesis that IL‐10 promoter polymorphisms may be associated with the progression of diabetic nephropathy (DN). Design Case‐controlled study. Patients Study subjects comprised of 515 DN patients, and 402 normoalbuminuric (DWN) T2DM patients. Measurements IL‐10 genotyping was done by PCR‐based assays, and the contributions of the IL‐10 polymorphic variants to DN were analysed by haplotype analysis and multivariate regression analysis. Results Decreased prevalence of (mutant) –819T allele and –819C/T genotype was seen in DN patients; neither the –1082G/A nor the –592C/A polymorphism was associated with DN. Three‐loci haplotype (–1082GA/–819CT/–592CA) analysis identified GTC as DN‐protective haplotype. Multivariate regression analysis confirmed the association of GTC haplotype ( P = 0·045; O R = 0·56, 95% CI: 0·31–0·99), and in addition identified GTA haplotype ( P = 0·044; O R = 0·54, 95% CI: 0·30–0·98) as independent predictors of DN after controlling for a number of covariates (age, sex, BMI; hypertension, glucose, HbA1c, DN duration, total cholesterol, medications). Conclusion This study suggests that IL‐10 promoter polymorphism influence the risk of nephropathy in Tunisian T2DM patients.